Nuffield Department of Medicine, University of Oxford, Oxford OX3 7LG, UK.
Women's Centre, John Radcliffe Hospital, Oxford University Hospitals, Oxford OX3 9DU, UK.
Trans R Soc Trop Med Hyg. 2022 Jun 1;116(6):509-522. doi: 10.1093/trstmh/trab180.
This review synthesises and appraises evidence on the effects of Ebola virus disease (EVD) in pregnancy. We searched bibliographic databases from dates of inception to November 2020, yielding 28 included studies. The absolute risk of maternal death associated with EVD was estimated at 67.8% (95% confidence interval [CI] 49.8 to 83.7, I2=85%, p<0.01) and the relative risk of death in pregnant women compared with non-pregnant women was estimated at 1.18 (95% CI 0.59 to 2.35, I2=31.0%, p=0.230). The absolute risk for foetal losses was estimated at 76.9% (95% CI 45.0 to 98.3, I2=96%, p<0.01) and neonatal death was 98.5% (95% CI 84.9 to 100, I2=0.0%, p=0.40). The gap analysis suggests limited or no data on the clinical course, non-fatal perinatal outcomes and EVD management in pregnant women. The review suggests that EVD has a high maternal and perinatal mortality, underscoring the urgent need for preventative and therapeutic solutions and improved screening and follow-up of pregnant women and newborns during outbreaks. There is not enough evidence to conclusively rule out pregnancy as a risk factor for mortality and there is limited evidence on the disease course, outcomes and management of EVD in pregnancy, and this supports the need for robust clinical trials and prospective studies that include pregnant women.
这篇综述综合评估了埃博拉病毒病(EVD)对妊娠的影响。我们从建库日期开始搜索文献数据库,一直到 2020 年 11 月,共纳入 28 项研究。埃博拉病毒病导致孕产妇死亡的绝对风险估计为 67.8%(95%置信区间[CI] 49.8 至 83.7,I2=85%,p<0.01),与非孕妇相比,孕妇的死亡相对风险估计为 1.18(95%CI 0.59 至 2.35,I2=31.0%,p=0.230)。胎儿丢失的绝对风险估计为 76.9%(95%CI 45.0 至 98.3,I2=96%,p<0.01),新生儿死亡为 98.5%(95%CI 84.9 至 100,I2=0.0%,p=0.40)。差距分析表明,关于妊娠妇女的临床病程、非致命围产期结局和 EVD 管理的数据有限或不存在。该综述表明,EVD 导致孕产妇和围产儿死亡率高,这突显了迫切需要预防和治疗方法,以及在暴发期间改善对孕妇和新生儿的筛查和随访。目前没有足够的证据明确排除妊娠是死亡的一个危险因素,关于妊娠期间 EVD 的疾病病程、结局和管理的证据有限,这支持需要进行强有力的临床试验和前瞻性研究,纳入孕妇。